Of respondents, 92 percent are not interested in expanding patient-reported outcome measures in clinical trials.
Concerning HEOR measures, drug companies often fund research, leading many payers to questions its validity. But, approximately 70 percent of executives are confident in HEOR measures when a neutral organization or institution supports the measure.
More articles on coding, billing and collections:
Majority of Americans support ACA in new poll: 3 insights
Trump administration to maintain ACA’s cost-sharing subsidies to payers during lawsuit: 4 points
The 4 secrets to scaling your business
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.